Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Company ParticipantsJames Molloy - Managing Director, Equity ResearchJoao Teixeira - Associate Professor in Division of NephrologyShakil Aslam - Chief Medical OfficerSharon McMahon - Associate Professor of MedicineVincent Angotti - CEOConference Call ParticipantsEd Arce - Managing Director, Senior Research AnalystNazibur Rahman - VP and Biopharmaceuticals Equity Research AnalystYuan Zhi - Senior Equity Research AnalystModeratorGood mo ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Company ParticipantsJoao Teixeira - Associate Professor in Division of NephrologyShakil Aslam - Chief Medical OfficerSharon McMahon - Associate Professor of MedicineVincent Angotti - CEOConference Call ParticipantsEd Arce - Managing Director and Senior Research AnalystJim Molloy - Managing Director and Biotechnology and Specialty Pharmaceuticals Equity Research AnalystNazibur Rahman - VP and Biopharmaceuticals Equity Research AnalystY ...

Talphera (NasdaqGM:TLPH) Q4 2025 Earnings call March 23, 2026 11:00 AM ET Speaker4Good morning, everyone, and welcome to the Talphera Virtual Analyst and Investor Event. At this time, all attendees are in a listen-only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Talphera website following the conclusion of the event. I'd now like to turn the call over to Vince Angotti, Chief Executive Officer ...

Core Insights - CorMedix Inc. reported Q3 2025 net revenue of $104.3 million and pro forma net revenue of $130.8 million, primarily driven by increased utilization of DefenCath by outpatient dialysis customers [4] - The company raised its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, with fourth quarter guidance set between $115 to $135 million [4] - CorMedix achieved a net income of $108.6 million for Q3 2025, significantly improving from a net loss of $2.8 million in Q3 2024, aided by a one-time tax benefit of $59.7 million [3][4] Financial Performance - Q3 2025 net revenue was $104.3 million, with DefenCath sales contributing $88.8 million [4] - Adjusted EBITDA for Q3 2025 was reported at $71.9 million, with basic and diluted EPS at $1.42 and $1.26, respectively [4][3] - Total operating expenses for Q3 2025 were $41.7 million, a 197% increase from $14.1 million in Q3 2024, driven by non-recurring costs related to the Melinta acquisition [5] Business Developments - CorMedix completed the acquisition of Melinta Therapeutics on August 29, 2025, with integration efforts proceeding faster than expected, estimating a synergy capture of approximately $30 million [4] - The company announced a rebranding to CorMedix Therapeutics, with all employees operating under the new name [4] - CorMedix completed enrollment in the Phase III ReSPECT study for Rezzayo in October 2025, expecting top-line data in Q2 2026 [4] Cash Position - As of September 30, 2025, CorMedix reported cash and short-term investments of $55.7 million, projecting year-end cash of approximately $100 million [6][4]